DUPILUMAB REDUCES SEVERE EXACERBATION RATES AND TOTAL IGE LEVELS IN CHILDREN WITH TYPE 2 ASTHMA, IRRESPECTIVE OF TRANSIENT INCREASE IN EOSINOPHILS
Excellence in Pediatrics Abstracts · 2025 · 17
DOI: 10.66584/eip2025-249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Excellence in Pediatrics Abstracts, 2025. Verfasst von Sharon Dell und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background: The efficacy of dupilumab in children in the age group 6–11 years with type 2 asthma was reported in VOYAGE (NCT02948959) and the EXCURSION (NCT03560466) extension study. The aim of the study was to evaluate the efficacy of dupilumab in children with and without an early increase in eosinophils (
Zitieren
APA
Dell, S., Guilbert, T., Deschildre, A., Phipatanakul, W., Papadopoulos, N., Murray, C., Xia, C., Moraco, A., Shams, M., & Bacharier, L. (2025). DUPILUMAB REDUCES SEVERE EXACERBATION RATES AND TOTAL IGE LEVELS IN CHILDREN WITH TYPE 2 ASTHMA, IRRESPECTIVE OF TRANSIENT INCREASE IN EOSINOPHILS. Excellence in Pediatrics Abstracts, 17. https://doi.org/10.66584/eip2025-249
Vancouver
Dell S, Guilbert T, Deschildre A, Phipatanakul W, Papadopoulos N, Murray C, et al. DUPILUMAB REDUCES SEVERE EXACERBATION RATES AND TOTAL IGE LEVELS IN CHILDREN WITH TYPE 2 ASTHMA, IRRESPECTIVE OF TRANSIENT INCREASE IN EOSINOPHILS. Excellence in Pediatrics Abstracts. 2025;17. doi:10.66584/eip2025-249
BibTeX
@article{Dell2025,
author = {Dell, Sharon and Guilbert, Theresa and Deschildre, Antoine and Phipatanakul, Wanda and Papadopoulos, Nikolaos and Murray, Clare and Xia, Changming and Moraco, Andrew and Shams, Marissa and Bacharier, Leonard},
title = {DUPILUMAB REDUCES SEVERE EXACERBATION RATES AND TOTAL IGE LEVELS IN CHILDREN WITH TYPE 2 ASTHMA, IRRESPECTIVE OF TRANSIENT INCREASE IN EOSINOPHILS},
journal = {Excellence in Pediatrics Abstracts},
year = {2025},
volume = {17},
doi = {10.66584/eip2025-249}
}
EUVIMED